What is the current stock price of Aytu BioPharma, Inc. (AYTU)?

As of the latest market data, Aytu BioPharma, Inc. (AYTU) is trading at $2.55. The stock has seen a loss of -0.39% today.

Does Aytu BioPharma, Inc. (AYTU) pay a dividend?

Based on current data, Aytu BioPharma, Inc. does not have a confirmed active dividend policy.

What is the market cap of Aytu BioPharma, Inc.?

The current market capitalization of Aytu BioPharma, Inc. (AYTU) is approximately unavailable.

AYTU

Aytu BioPharma, Inc.·Healthcare

2.55

0.391%(−0.01)

Market Closed

3.15

23.529%(+0.60)

After Hours

Last Updated: — ET

52W L: $0.9852W H: $3.07

AYTU NEWS

defenseworld.net

Feb 16

Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1 year

seekingalpha.com

Feb 3

Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript

zacks.com

Feb 3

Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates

Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.28 per share a year ago.

accessnewswire.com

Feb 3

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 second quarter.

zacks.com

Feb 2

New Strong Sell Stocks for February 2nd

AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.

accessnewswire.com

Jan 27

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m.

Company Profile

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

102

IPO Date

2008-09-25

Beta

0.28

Websiteaytubio.com↗